Associations between dietary fatty acid intakes and risk of coronary heart disease (CHD) are not entirely consistent in prospective studies in the U.S. and Europe. Such studies in Japan are rare. The objective of this study was to examine the association between dietary total, saturated (SFA), and polyunsaturated (PUFA) fatty acids, cholesterol intake and CHD mortality using the dataset of NIPPON DATA90. At the baseline in 1990, we performed blood biochemical measurements and a nutritional survey on participants from 300 randomly selected districts. After exclusion of participants with a history of CHD and/or stroke at the baseline, we followed 7,819 community residents (3,254 men and 4,565 women, age ≥ 30) for 15 years. We estimated individual nutrient intakes among family members by weighed food records in three consecutive representative days. During the follow-up, there were 42 CHD deaths in men and 30 in women. Mean daily SFA and PUFA % calorie intakes were 5.90±1.36%, and 5.59±1.30%, respectively in men, and 6.48±1.53%, and 6.08±1.14% in women. A Cox analysis adjusted for age, vegetable and fruit intakes, and other confounders in women found that SFA intake was significantly associated with CHD mortality (hazards ratio per one quintile increment=1.34, 95% confidence intervals: 1.02-1.74, P=0.03), while no such association was noted in men. No associations were found between other fat intakes and CHD mortality in men or women. In conclusion, SFA intake was positively associated with CHD mortality independent of confounders in women, but not in men.
Keywords: Cohort study, coronary heart disease, fatty acid intakes, mortality, saturated fatty acids, polyunsaturated fatty acids, fruits, vegetable, disease
Computational Biological Analysis Reveals a Role for Nitric Oxide Synthase and Adiponectin in the Pathobiology of Insulin Resistance Syndrome and Coronary Artery Disease
Current Nutrition & Food Science Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Lipoprotein Lipase and Atherosclerosis
Current Vascular Pharmacology Translational Applications of Tissue Engineering in Cardiovascular Medicine
Current Pharmaceutical Design The Emergence of Plasma Membrane Calcium Pump as a Novel Therapeutic Target for Heart Disease
Mini-Reviews in Medicinal Chemistry Mediterranean Diet And Longevity: An Example Of Nutraceuticals?
Current Vascular Pharmacology Does HbA1cc Play a Role in the Development of Cardiovascular Diseases?
Current Pharmaceutical Design Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Current Pharmaceutical Design The Coronary Artery Risk Detection in Appalachian Communities (CARDIAC) Project: An 18 Year Review
Current Pediatric Reviews Statin Therapy for Native and Peri-Interventional Coronary Heart Disease
Current Molecular Medicine Prevalence, Incidence and Risk Factors of Chronic Heart Failure in the Type 2 Diabetic Population: Systematic Review
Current Diabetes Reviews Non Invasive Imaging of Myocardial Infarction with Computed Tomography and Magnetic Resonance
Current Vascular Pharmacology Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]
Current Vascular Pharmacology Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease
Current Pharmaceutical Design Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Current Drug Metabolism Emerging Therapeutic Targets for Metabolic Syndrome: Lessons from Animal Models
Endocrine, Metabolic & Immune Disorders - Drug Targets The Impact of the Emerging Genomics Data on the Management of Agerelated Phenotypes in the Context of Cellular Senescence
Current Drug Targets Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Current Drug Targets